| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement
|
|
|
2013
|
|
12 |
p. 1003-1005
|
artikel
|
| 2 |
Acknowledgement to Referees
|
|
|
2016
|
|
12 |
p. 1121-1125
|
artikel
|
| 3 |
Acknowledgement to Referees
|
|
|
|
|
12 |
p. 1243-1247
|
artikel
|
| 4 |
Acknowledgement to Referees
|
|
|
2014
|
|
12 |
p. 1099-1102
|
artikel
|
| 5 |
Acknowledgement to Referees
|
|
|
2017
|
|
12 |
p. 1023-1027
|
artikel
|
| 6 |
Acknowledgement to Referees
|
|
|
2015
|
|
12 |
p. 971-973
|
artikel
|
| 7 |
Acknowledgement to Referees
|
|
|
2018
|
|
12 |
p. 1079-1083
|
artikel
|
| 8 |
Acknowledgement to Referees
|
|
|
|
|
12 |
p. 1141-1145
|
artikel
|
| 9 |
Acknowledgement to Referees
|
|
|
|
|
12 |
p. 1233-1238
|
artikel
|
| 10 |
Acknowledgement to Referees
|
|
|
|
|
12 |
p. 1201-1203
|
artikel
|
| 11 |
Acknowledgement to Referees
|
|
|
|
|
12 |
p. 1079-1083
|
artikel
|
| 12 |
Acknowledgement to Referees
|
|
|
|
|
12 |
p. 1021-1026
|
artikel
|
| 13 |
Acknowledgments
|
|
|
2012
|
|
12 |
p. 1013-1015
|
artikel
|
| 14 |
Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)
|
Lattanzi, Simona
|
|
|
|
12 |
p. 1289-1301
|
artikel
|
| 15 |
Adverse Endocrine and Metabolic Effects of Psychotropic Drugs
|
Bhuvaneswar, Chaya G.
|
|
2009
|
|
12 |
p. 1003-1021
|
artikel
|
| 16 |
Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review
|
Besag, Frank M. C.
|
|
|
|
12 |
p. 1167-1186
|
artikel
|
| 17 |
A Multicenter, Randomized, Double-Blind, Positive-Controlled, Non-Inferiority, Phase III Clinical Trial Evaluating the Efficacy and Safety of Emulsified Isoflurane for Anesthesia Induction in Patients
|
Yang, Hui
|
|
|
|
12 |
p. 1301-1311
|
artikel
|
| 18 |
Animal Migraine Models for Drug Development: Status and Future Perspectives
|
Jansen-Olesen, Inger
|
|
2013
|
|
12 |
p. 1049-1068
|
artikel
|
| 19 |
Antipsychotic-Induced Constipation: A Review of the Pathogenesis, Clinical Diagnosis, and Treatment
|
Xu, Yue
|
|
|
|
12 |
p. 1265-1274
|
artikel
|
| 20 |
An Update on Vitamin D and Disease Activity in Multiple Sclerosis
|
Smolders, Joost
|
|
|
|
12 |
p. 1187-1199
|
artikel
|
| 21 |
A Single-Dose Pilot Trial of Intranasal Rapid-Acting Insulin in Apolipoprotein E4 Carriers with Mild–Moderate Alzheimer’s Disease
|
Rosenbloom, Michael H.
|
|
2014
|
|
12 |
p. 1185-1189
|
artikel
|
| 22 |
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential
|
Klistorner, Alexander
|
|
2018
|
|
12 |
p. 1159-1171
|
artikel
|
| 23 |
Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential
|
Klistorner, Alexander
|
|
|
|
12 |
p. 1159-1171
|
artikel
|
| 24 |
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms
|
Werneck, Maira Aguiar
|
|
2018
|
|
12 |
p. 1113-1129
|
artikel
|
| 25 |
A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms
|
Werneck, Maira Aguiar
|
|
|
|
12 |
p. 1113-1129
|
artikel
|
| 26 |
Authors’ Reply to Pereira Ribeiro et al.: Comment on “Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta‑Analysis”
|
Gartlehner, Gerald
|
|
|
|
12 |
p. 1335-1336
|
artikel
|
| 27 |
Authors’ Reply to Singh and Balasundaram: Comment on “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder”
|
Nasser, Azmi
|
|
|
|
12 |
p. 1333-1335
|
artikel
|
| 28 |
Authors’ Reply to Whitlock: Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence
|
Ignatowski, Tracey A.
|
|
2014
|
|
12 |
p. 1207-1213
|
artikel
|
| 29 |
Bacterial Meningitis
|
Williams, Amanda J.
|
|
|
|
12 |
p. 909-919
|
artikel
|
| 30 |
B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence
|
Kinzel, Silke
|
|
2016
|
|
12 |
p. 1137-1148
|
artikel
|
| 31 |
Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson’s Disease: Therapeutic Rationale and Current Status
|
Swart, Tara
|
|
2016
|
|
12 |
p. 1127-1135
|
artikel
|
| 32 |
Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis
|
Bhagavan, Chiranth
|
|
|
|
12 |
p. 1217-1228
|
artikel
|
| 33 |
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease
|
Patel, Jaimin
|
|
|
|
12 |
p. 1249-1267
|
artikel
|
| 34 |
Clinically Significant Drug–Drug Interactions with Agents for Attention-Deficit/Hyperactivity Disorder
|
Schoretsanitis, Georgios
|
|
|
|
12 |
p. 1201-1222
|
artikel
|
| 35 |
Clinically Significant Drug Interactions with Atypical Antipsychotics
|
Kennedy, William Klugh
|
|
2013
|
|
12 |
p. 1021-1048
|
artikel
|
| 36 |
Clozapine and Gastrointestinal Hypomotility
|
Cohen, Dan
|
|
2017
|
|
12 |
p. 1083-1091
|
artikel
|
| 37 |
Comment on: “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention Deficit/Hyperactivity Disorder”
|
Singh, Alok
|
|
|
|
12 |
p. 1331-1332
|
artikel
|
| 38 |
Comment on: “Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence”
|
Whitlock, David R.
|
|
2014
|
|
12 |
p. 1205-1206
|
artikel
|
| 39 |
Comment on “Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis”
|
Pereira Ribeiro, Johanne
|
|
|
|
12 |
p. 1333-1334
|
artikel
|
| 40 |
Comparative Effectiveness of Device-Aided Therapies on Quality of Life and Off-Time in Advanced Parkinson’s Disease: A Systematic Review and Bayesian Network Meta-analysis
|
Antonini, Angelo
|
|
|
|
12 |
p. 1269-1283
|
artikel
|
| 41 |
Context is a Critical for Psychoactive Drug Effects
|
Greenway, Kyle T.
|
|
|
|
12 |
p. 1065-1068
|
artikel
|
| 42 |
Correction to: Adjunctive Brivaracetam in Focal Epilepsy: Real‑World Evidence from the BRIVAracetam add‑on First Italian netwoRk Study (BRIVAFIRST)
|
Lattanzi, Simona
|
|
|
|
12 |
p. 1329-1331
|
artikel
|
| 43 |
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
|
Hey, John A.
|
|
2018
|
|
12 |
p. 1185
|
artikel
|
| 44 |
Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
|
Hey, John A.
|
|
|
|
12 |
p. 1185
|
artikel
|
| 45 |
Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
|
Gudesblatt, Mark
|
|
2018
|
|
12 |
p. 1183
|
artikel
|
| 46 |
Correction to: Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
|
Gudesblatt, Mark
|
|
|
|
12 |
p. 1183
|
artikel
|
| 47 |
Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
|
Zimmermann, Marita
|
|
2018
|
|
12 |
p. 1145-1157
|
artikel
|
| 48 |
Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis
|
Zimmermann, Marita
|
|
|
|
12 |
p. 1145-1157
|
artikel
|
| 49 |
Drug-Induced Cerebellar Ataxia: A Systematic Review
|
Gaalen, J. van
|
|
2014
|
|
12 |
p. 1139-1153
|
artikel
|
| 50 |
Drug Safety Analysis in a Real-Life Cohort of Parkinson’s Disease Patients with Polypharmacy
|
Müller-Rebstein, Saskia
|
|
2017
|
|
12 |
p. 1093-1102
|
artikel
|
| 51 |
Effectiveness of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Physical Injuries: A Systematic Review and Meta-Analysis of Observational Studies
|
Man, Kenneth K. C.
|
|
2017
|
|
12 |
p. 1043-1055
|
artikel
|
| 52 |
Effect of BI 1358894 on Cholecystokinin-Tetrapeptide (CCK-4)-Induced Anxiety, Panic Symptoms, and Stress Biomarkers: A Phase I Randomized Trial in Healthy Males
|
Goettel, Markus
|
|
|
|
12 |
p. 1099-1109
|
artikel
|
| 53 |
Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System
|
Dinesh, Ayushi Anna
|
|
|
|
12 |
p. 1229-1251
|
artikel
|
| 54 |
Effects of Single and Multiple Ascending Doses of BI 1358894 in Healthy Male Volunteers on Safety, Tolerability and Pharmacokinetics: Two Phase I Partially Randomised Studies
|
Fuertig, René
|
|
|
|
12 |
p. 1081-1097
|
artikel
|
| 55 |
Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study
|
Dittmann, Ralf W.
|
|
2013
|
|
12 |
p. 1081-1092
|
artikel
|
| 56 |
Emergency Department Initiation of Buprenorphine for Opioid Use Disorder: Current Status, and Future Potential
|
Fox, Lindsay
|
|
|
|
12 |
p. 1147-1154
|
artikel
|
| 57 |
Erratum to: Systematic Review and Meta-Analysis of the Efficacy and Safety of Perampanel in the Treatment of Partial-Onset Epilepsy
|
Hsu, Warrington W. Q.
|
|
2013
|
|
12 |
p. 1143
|
artikel
|
| 58 |
Evaluation of a Rapid Topiramate Titration Scheme for the Early Detection of Cognitive Side Effects
|
Witt, Juri-Alexander
|
|
|
|
12 |
p. 1325-1330
|
artikel
|
| 59 |
Evaluation of Prescription Practices of Domperidone in Parkinson’s Disease: A Cross Sectional Study Among French Neurologists
|
Lastennet, Diane
|
|
|
|
12 |
p. 1267-1274
|
artikel
|
| 60 |
Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis
|
Golan, Maya
|
|
|
|
12 |
p. 1229-1237
|
artikel
|
| 61 |
Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
|
Banaschewski, Tobias
|
|
2014
|
|
12 |
p. 1191-1203
|
artikel
|
| 62 |
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
|
Freeman, Léorah
|
|
|
|
12 |
p. 1285-1299
|
artikel
|
| 63 |
Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
|
Gudesblatt, Mark
|
|
2018
|
|
12 |
p. 1173-1181
|
artikel
|
| 64 |
Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis
|
Gudesblatt, Mark
|
|
|
|
12 |
p. 1173-1181
|
artikel
|
| 65 |
Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy
|
Patel, Sima I.
|
|
2015
|
|
12 |
p. 1009-1022
|
artikel
|
| 66 |
Ischemic and Thrombotic Events Associated with Concomitant Xa-inhibiting Direct Oral Anticoagulants and Antiepileptic Drugs: Analysis of the FDA Adverse Event Reporting System (FAERS)
|
Perlman, Amichai
|
|
|
|
12 |
p. 1223-1228
|
artikel
|
| 67 |
l-Acetyl-carnitine in Patients with Carpal Tunnel Syndrome: Effects on Nerve Protection, Hand Function and Pain
|
Cruccu, Giorgio
|
|
2017
|
|
12 |
p. 1103-1111
|
artikel
|
| 68 |
Lacosamide: A Review of Its Use as Adjunctive Therapy in the Management of Partial-Onset Seizures
|
Hoy, Sheridan M.
|
|
2013
|
|
12 |
p. 1125-1142
|
artikel
|
| 69 |
Levetiracetam Interaction with Direct Oral Anticoagulants: A Pharmacovigilance Study
|
Abou Kaoud, Mohammed
|
|
|
|
12 |
p. 1111-1121
|
artikel
|
| 70 |
Levetiracetam versus Phenytoin for the Pharmacotherapy of Benzodiazepine-Refractory Status Epilepticus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
|
Xue, Tao
|
|
|
|
12 |
p. 1205-1215
|
artikel
|
| 71 |
Long-Term Treatment Over 52 Weeks with Monthly Fremanezumab in Drug-Resistant Migraine: A Prospective Multicenter Cohort Study
|
Caponnetto, Valeria
|
|
|
|
12 |
p. 1069-1080
|
artikel
|
| 72 |
Mechanisms of Antioxidant Induction with High-Dose N-Acetylcysteine in Childhood Cerebral Adrenoleukodystrophy
|
Kartha, Reena V.
|
|
2015
|
|
12 |
p. 1041-1047
|
artikel
|
| 73 |
Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis
|
Ellul, Pierre
|
|
2018
|
|
12 |
p. 1103-1112
|
artikel
|
| 74 |
Metformin for Weight Gain Associated with Second-Generation Antipsychotics in Children and Adolescents: A Systematic Review and Meta-Analysis
|
Ellul, Pierre
|
|
|
|
12 |
p. 1103-1112
|
artikel
|
| 75 |
Methamphetamine Psychosis: Epidemiology and Management
|
Glasner-Edwards, Suzette
|
|
2014
|
|
12 |
p. 1115-1126
|
artikel
|
| 76 |
Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications
|
Liu, Melinda
|
|
2016
|
|
12 |
p. 1149-1168
|
artikel
|
| 77 |
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
|
Gust, Juliane
|
|
2018
|
|
12 |
p. 1091-1101
|
artikel
|
| 78 |
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
|
Gust, Juliane
|
|
|
|
12 |
p. 1091-1101
|
artikel
|
| 79 |
New Hope for Survivors of Stroke and Traumatic Brain Injury
|
Clark, Ian
|
|
2012
|
|
12 |
p. 1071-1072
|
artikel
|
| 80 |
Novel Delivery Systems for Nicotine Replacement Therapy as an Aid to Smoking Cessation and for Harm Reduction: Rationale, and Evidence for Advantages over Existing Systems
|
Shahab, Lion
|
|
2013
|
|
12 |
p. 1007-1019
|
artikel
|
| 81 |
Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer’s Disease and Other Neurodegenerative Diseases
|
Calsolaro, Valeria
|
|
2015
|
|
12 |
p. 1023-1039
|
artikel
|
| 82 |
Novel IDH1-Targeted Glioma Therapies
|
Karpel-Massler, Georg
|
|
|
|
12 |
p. 1155-1166
|
artikel
|
| 83 |
Nusinersen: A Review in 5q Spinal Muscular Atrophy
|
Hoy, Sheridan M.
|
|
|
|
12 |
p. 1317-1328
|
artikel
|
| 84 |
Olfactory Reference Disorder: Diagnosis, Epidemiology and Management
|
Thomas, Eileen
|
|
2015
|
|
12 |
p. 999-1007
|
artikel
|
| 85 |
OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use
|
Frampton, James E.
|
|
|
|
12 |
p. 1287-1298
|
artikel
|
| 86 |
Perampanel
|
Plosker, Greg L.
|
|
2012
|
|
12 |
p. 1085-1096
|
artikel
|
| 87 |
Pharmacogenetics and Imaging–Pharmacogenetics of Antidepressant Response: Towards Translational Strategies
|
Lett, Tristram A.
|
|
2016
|
|
12 |
p. 1169-1189
|
artikel
|
| 88 |
Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects
|
Berger, Benjamin
|
|
|
|
12 |
p. 1253-1266
|
artikel
|
| 89 |
Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease
|
Schaeffer, Eva
|
|
2014
|
|
12 |
p. 1155-1184
|
artikel
|
| 90 |
Pharmacologic Therapies for Malignant Glioma: A Guide for Clinicians
|
Soffietti, Riccardo
|
|
2014
|
|
12 |
p. 1127-1137
|
artikel
|
| 91 |
Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus in Adults: A Prospective Randomized Controlled Trial in China
|
Su, Yingying
|
|
2016
|
|
12 |
p. 1201-1207
|
artikel
|
| 92 |
Potential of Ligands for Trace Amine-Associated Receptor 1 (TAAR1) in the Management of Substance Use Disorders
|
Wu, Ruyan
|
|
|
|
12 |
p. 1239-1248
|
artikel
|
| 93 |
Pregabalin for the Treatment of Drug and Alcohol Withdrawal Symptoms: A Comprehensive Review
|
Freynhagen, Rainer
|
|
2016
|
|
12 |
p. 1191-1200
|
artikel
|
| 94 |
Rediscovering Trazodone for the Treatment of Major Depressive Disorder
|
Fagiolini, Andrea
|
|
2012
|
|
12 |
p. 1033-1049
|
artikel
|
| 95 |
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
|
Bouvy, Jacoline C.
|
|
2018
|
|
12 |
p. 1085-1090
|
artikel
|
| 96 |
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
|
Bouvy, Jacoline C.
|
|
|
|
12 |
p. 1085-1090
|
artikel
|
| 97 |
Risks of Cardiac Valve Regurgitation and Heart Failure Associated with Ergot- and Non-Ergot-Derived Dopamine Agonist Use in Patients with Parkinson’s Disease: A Systematic Review of Observational Studies
|
Tran, Tanja
|
|
2015
|
|
12 |
p. 985-998
|
artikel
|
| 98 |
Scopolamine Detoxification Technique for Heroin Dependence: A Randomized Trial
|
Liu, Sheng
|
|
2013
|
|
12 |
p. 1093-1102
|
artikel
|
| 99 |
Second Generation Antipsychotic-Induced Type 2 Diabetes: A Role for the Muscarinic M3 Receptor
|
Weston-Green, Katrina
|
|
2013
|
|
12 |
p. 1069-1080
|
artikel
|
| 100 |
Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury
|
Tobinick, Edward
|
|
2012
|
|
12 |
p. 1051-1070
|
artikel
|
| 101 |
Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease
|
Duty, Susan
|
|
2012
|
|
12 |
p. 1017-1032
|
artikel
|
| 102 |
Targeting Neuroinflammation to Treat Alzheimer’s Disease
|
Ardura-Fabregat, A.
|
|
2017
|
|
12 |
p. 1057-1082
|
artikel
|
| 103 |
Targeting the Nicotinic Cholinergic System to Treat Attention-Deficit/Hyperactivity Disorder: Rationale and Progress to Date
|
Potter, Alexandra S.
|
|
2014
|
|
12 |
p. 1103-1113
|
artikel
|
| 104 |
Teriflunomide: A Review of Its Use in Relapsing Multiple Sclerosis
|
Garnock-Jones, Karly P.
|
|
2013
|
|
12 |
p. 1103-1123
|
artikel
|
| 105 |
The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review
|
Pouyan, Niloufar
|
|
|
|
12 |
p. 1027-1063
|
artikel
|
| 106 |
The Impact of Lithium on Brain Function in Bipolar Disorder: An Updated Review of Functional Magnetic Resonance Imaging Studies
|
Bergamelli, Emilio
|
|
|
|
12 |
p. 1275-1287
|
artikel
|
| 107 |
The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values
|
Lee, Lik Hang N.
|
|
2015
|
|
12 |
p. 975-983
|
artikel
|
| 108 |
The Psychiatric Inclusion and Exclusion Criteria in Placebo-Controlled Monotherapy Trials of Bipolar Depression: An Analysis of Studies of the Past 20 Years
|
Zimmerman, Mark
|
|
2016
|
|
12 |
p. 1209-1218
|
artikel
|
| 109 |
Therapeutic Potential of Ursolic Acid to Manage Neurodegenerative and Psychiatric Diseases
|
Ramos-Hryb, Ana B.
|
|
2017
|
|
12 |
p. 1029-1041
|
artikel
|
| 110 |
Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study
|
Pilo de la Fuente, Belen
|
|
|
|
12 |
p. 1275-1286
|
artikel
|
| 111 |
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis
|
Ip, Bonaventure Y.
|
|
|
|
12 |
p. 1313-1324
|
artikel
|
| 112 |
Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials
|
Watson, Nathaniel F.
|
|
|
|
12 |
p. 1303-1315
|
artikel
|
| 113 |
Vitamin D Supplementation and Cognition in Adults: A Systematic Review of Randomized Controlled Trials
|
Beauchet, Olivier
|
|
|
|
12 |
p. 1249-1264
|
artikel
|
| 114 |
VMAT2 Inhibitors in Neuropsychiatric Disorders
|
Tarakad, Arjun
|
|
2018
|
|
12 |
p. 1131-1144
|
artikel
|
| 115 |
VMAT2 Inhibitors in Neuropsychiatric Disorders
|
Tarakad, Arjun
|
|
|
|
12 |
p. 1131-1144
|
artikel
|
| 116 |
Ziprasidone
|
Harrison, Tracy Swainston
|
|
|
|
12 |
p. 1027-1052
|
artikel
|
Tijdschrift beschrijving